Smallpox - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H1 2017, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 3, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smallpox - Overview
Smallpox - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Smallpox - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smallpox - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioFactura Inc
CEL-SCI Corp
Chimerix Inc
CJ HealthCare Corp
EpiVax Inc
N & N Pharmaceuticals Inc
SIGA Technologies Inc
Takeda Pharmaceutical Company Ltd
Tonix Pharmaceuticals Holding Corp
Smallpox - Drug Profiles
(plague + small pox) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
24a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brincidofovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-40011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Smallpox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIR-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smallpox - Dormant Projects
Smallpox - Discontinued Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-801 at 9th Annual Biotech Showcase Conference
Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
Nov 23, 2016: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE Smallpox Vaccine
Sep 21, 2016: SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full
Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
Dec 23, 2014: Chimerix Provides Recap of 2014 Events
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Smallpox, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Smallpox - Pipeline by Bavarian Nordic A/S, H1 2017
Smallpox - Pipeline by BioFactura Inc, H1 2017
Smallpox - Pipeline by CEL-SCI Corp, H1 2017
Smallpox - Pipeline by Chimerix Inc, H1 2017
Smallpox - Pipeline by CJ HealthCare Corp, H1 2017
Smallpox - Pipeline by EpiVax Inc, H1 2017
Smallpox - Pipeline by N & N Pharmaceuticals Inc, H1 2017
Smallpox - Pipeline by SIGA Technologies Inc, H1 2017
Smallpox - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017
Smallpox - Dormant Projects, H1 2017
Smallpox - Dormant Projects, H1 2017 (Contd..1), H1 2017
Smallpox - Discontinued Products, H1 2017